Charles Schwab Investment Management Inc. boosted its position in Savara Inc (NASDAQ:SVRA – Free Report) by 238.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 911,617 shares of the company’s stock after purchasing an additional 642,259 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Savara were worth $3,865,000 as of its most recent SEC filing.
Several other institutional investors have also recently made changes to their positions in SVRA. Choreo LLC bought a new position in Savara in the 2nd quarter worth $59,000. DRW Securities LLC purchased a new position in shares of Savara in the second quarter valued at about $62,000. Principal Financial Group Inc. boosted its stake in Savara by 64.4% in the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock worth $72,000 after purchasing an additional 6,973 shares during the period. Profund Advisors LLC bought a new stake in shares of Savara during the second quarter valued at approximately $105,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Savara by 95.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 31,658 shares of the company’s stock valued at $134,000 after purchasing an additional 15,423 shares during the last quarter. Institutional investors own 87.93% of the company’s stock.
Wall Street Analysts Forecast Growth
SVRA has been the topic of several research reports. Evercore ISI restated an “in-line” rating and issued a $5.00 price target (down previously from $7.00) on shares of Savara in a research report on Wednesday, November 13th. HC Wainwright decreased their price target on Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $9.00 price objective on shares of Savara in a research note on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.17.
Insider Activity
In other news, Director Joseph S. Mccracken purchased 20,000 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were acquired at an average cost of $2.95 per share, with a total value of $59,000.00. Following the completion of the acquisition, the director now owns 210,837 shares of the company’s stock, valued at $621,969.15. This trade represents a 10.48 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 5.13% of the company’s stock.
Savara Trading Down 4.2 %
NASDAQ SVRA opened at $3.21 on Friday. The stock has a market cap of $550.90 million, a PE ratio of -7.47 and a beta of 0.92. Savara Inc has a 12 month low of $2.82 and a 12 month high of $5.70. The company’s 50-day moving average price is $3.52 and its 200-day moving average price is $4.02. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13.
Savara (NASDAQ:SVRA – Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.11). Equities research analysts forecast that Savara Inc will post -0.45 earnings per share for the current year.
Savara Company Profile
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Featured Articles
- Five stocks we like better than Savara
- Stock Market Sectors: What Are They and How Many Are There?
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- Pros And Cons Of Monthly Dividend Stocks
- Texas Instruments: The Old-School Tech Titan Still Delivering
- 5 discounted opportunities for dividend growth investors
- GRAIL: Biotech Stock Targeting $100B Cancer Market
Want to see what other hedge funds are holding SVRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Savara Inc (NASDAQ:SVRA – Free Report).
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.